Literature DB >> 1772298

Calcitonin treatment for intersternocostoclavicular ossification: clinical experience in two cases.

T Misaki1, S Dokoh, E Mori.   

Abstract

Intersternocostoclavicular ossification is a benign arthro-osteitis of the upper anterior chest of unknown cause. Two patients with acute exacerbation of this disorder were successfully treated with intramuscular injections of an eel calcitonin analogue (40 units three times a week). Besides symptomatic relief of local pain and swelling, serial scintigrams showed quantitative improvement in radiophosphonate uptake. The rapid alleviation of pain implies that the hormone has a central analgesic effect, in addition to its direct influence on bone cells and antiinflammatory action. In one patient the disease was associated with palmoplantar pustulosis, which was cured with oral colchicine, whereas the other patient did not have such skin lesions. Despite a hypothetical link between palmoplantar pustulosis and intersternocostoclavicular ossification, colchicine had no beneficial impact on the bone pain. Salmon calcitonin delivered by nasal spray was tried for the second patient but failed, probably because of insufficient drug delivery. The initial favourable results described here warrant future use of calcitonin injection on a larger number of patients with intersternocostoclavicular ossification.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1772298      PMCID: PMC1004565          DOI: 10.1136/ard.50.11.813

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  19 in total

1.  Effects of intracerebroventricular calcitonin in the conscious rabbit.

Authors:  A Pecile; S Ferri; P C Braga; V R Olgiati
Journal:  Experientia       Date:  1975-03-15

2.  A radionuclide and radiographic diagnosis of sternocostoclavicular hyperostosis.

Authors:  L Rosenthall; D L Burke
Journal:  Clin Nucl Med       Date:  1986-05       Impact factor: 7.794

3.  [Effects of prolonged administration of various calcitonins in human osteoporosis: clinical, histologic and microradiographic study].

Authors:  B Langer; J de Siebenthal; L Baud; C A Baud; R S Mach
Journal:  Ann Med Interne (Paris)       Date:  1971-02

4.  Immunohistochemical demonstration of calcitonin binding to specific cell types in fixed rat bone tissue.

Authors:  L G Rao; J N Heersche; L L Marchuk; W Sturtridge
Journal:  Endocrinology       Date:  1981-05       Impact factor: 4.736

5.  Sternocostoclavicular hyperostosis.

Authors:  D Resnick
Journal:  AJR Am J Roentgenol       Date:  1980-12       Impact factor: 3.959

6.  Treatment of pustulosis palmaris et plantaris with oral doses of colchicine.

Authors:  M Takigawa; Y Miyachi; M Uehara; H Tagami
Journal:  Arch Dermatol       Date:  1982-07

7.  Conceptual understanding of pustulosis palmaris et plantaris as an immune complex disease due to focal tonsillar infections.

Authors:  N Yamanaka; S Sambe; A Kataura
Journal:  Acta Otolaryngol Suppl       Date:  1983

8.  Incidence of arthro-osteitis in patients with pustulosis palmaris et plantaris.

Authors:  H Sonozaki; M Kawashima; O Hongo; H Yaoita; M Ikeno; M Matsuura; K Okai; A Azuma
Journal:  Ann Rheum Dis       Date:  1981-12       Impact factor: 19.103

9.  Immunohistological studies on tonsils with recurrent tonsillitis and focus-tonsil with pustulosis palmaris et plantaris.

Authors:  K Kuki; T Tabata
Journal:  Acta Otolaryngol Suppl       Date:  1984

10.  Effects of human calcitonin on pain in the treatment of Tietze's syndrome.

Authors:  G Ricevuti
Journal:  Clin Ther       Date:  1985       Impact factor: 3.393

View more
  2 in total

1.  Acquired hyperostosis syndrome--AHYS--(sternocostoclavicular hyperostosis, pustulotic arthro-osteitis, SAPHO-syndrome): bone scintigraphy of the anterior chest wall.

Authors:  W Dihlmann; S W Dihlmann; L Hering
Journal:  Clin Rheumatol       Date:  1997-01       Impact factor: 2.980

2.  Sternocostoclavicular hyperostosis: a review.

Authors:  Matthew B Carroll
Journal:  Ther Adv Musculoskelet Dis       Date:  2011-04       Impact factor: 5.346

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.